292 related articles for article (PubMed ID: 25631351)
1. Relation between ticagrelor response and levels of circulating reticulated platelets in patients with non-ST elevation acute coronary syndromes.
Vaduganathan M; Zemer-Wassercug N; Rechavia E; Lerman-Shivek H; Perl L; Leshem-Lev D; Orvin K; Kornowski R; Lev EI
J Thromb Thrombolysis; 2015 Aug; 40(2):211-7. PubMed ID: 25631351
[TBL] [Abstract][Full Text] [Related]
2. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome.
Bonello L; Laine M; Camoin-Jau L; Noirot F; Guieu R; Dignat-George F; Paganelli F; Frere C
Thromb Haemost; 2015 Oct; 114(4):702-7. PubMed ID: 26311415
[TBL] [Abstract][Full Text] [Related]
3. Response to prasugrel and levels of circulating reticulated platelets in patients with ST-segment elevation myocardial infarction.
Perl L; Lerman-Shivek H; Rechavia E; Vaduganathan M; Leshem-Lev D; Zemer-Wassercug N; Dadush O; Codner P; Bental T; Battler A; Kornowski R; Lev EI
J Am Coll Cardiol; 2014 Feb; 63(6):513-7. PubMed ID: 24148715
[TBL] [Abstract][Full Text] [Related]
4. Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes.
Joshi RR; Hossain R; Morton AC; Ecob R; Judge HM; Wales C; Walker JV; Karunakaran A; Storey RF
Platelets; 2014; 25(6):416-22. PubMed ID: 24111601
[TBL] [Abstract][Full Text] [Related]
5. Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome.
Bernlochner I; Goedel A; Plischke C; Schüpke S; Haller B; Schulz C; Mayer K; Morath T; Braun S; Schunkert H; Siess W; Kastrati A; Laugwitz KL
Eur Heart J; 2015 Dec; 36(45):3202-10. PubMed ID: 26216931
[TBL] [Abstract][Full Text] [Related]
6. Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.
Kerneis M; Silvain J; Abtan J; Hauguel M; Barthélémy O; Payot L; Brugier D; Galier S; Collet JP; Montalescot G
Arch Cardiovasc Dis; 2015 Oct; 108(10):502-10. PubMed ID: 26113480
[TBL] [Abstract][Full Text] [Related]
7. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
[TBL] [Abstract][Full Text] [Related]
8. Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study.
Bernlochner I; Mayer K; Orban M; Morath T; Jaitner J; Rössner L; Gross L; Laugwitz KL; Kastrati A; Sibbing D
Platelets; 2016 Dec; 27(8):796-804. PubMed ID: 27275651
[TBL] [Abstract][Full Text] [Related]
9. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
[TBL] [Abstract][Full Text] [Related]
10. Circulating reticulated platelets over time in patients with myocardial infarction treated with prasugrel or ticagrelor.
Eisen A; Lerman-Shivek H; Perl L; Rechavia E; Leshem-Lev D; Zemer-Wassercug N; Dadush O; Kazum S; Codner P; Kornowski R; Lev EI
J Thromb Thrombolysis; 2015 Jul; 40(1):70-5. PubMed ID: 25481810
[TBL] [Abstract][Full Text] [Related]
11. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
[TBL] [Abstract][Full Text] [Related]
12. Chewing versus Swallowing Ticagrelor to Accelerate Platelet Inhibition in Acute Coronary Syndrome - the CHEERS study. For The PLATIS (Platelets and Thrombosis in Sheba) Study Group.
Asher E; Frydman S; Katz M; Regev E; Sabbag A; Mazin I; Abu-Much A; Kukuy A; Mazo A; Erez A; Berkovitch A; Narodistky M; Barbash I; Segev A; Beigel R; Matetzky S
Thromb Haemost; 2017 Apr; 117(4):727-733. PubMed ID: 28150850
[TBL] [Abstract][Full Text] [Related]
13. Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention.
Laine M; Toesca R; Berbis J; Frere C; Barnay P; Pansieri M; Peyre JP; Michelet P; Bessereau J; Camilleri E; Helaf O; Camaleonte M; Paganelli F; Dignat-George F; Bonello L
Thromb Res; 2013 Jul; 132(1):e15-8. PubMed ID: 23726090
[TBL] [Abstract][Full Text] [Related]
14. Comparison of half- and standard-dose ticagrelor in Chinese patients with NSTE-ACS.
Xue HJ; Shi J; Liu B; Wang DY; Dong ZX; Guo H; Kong YH; Sheng L; Shao Q; Sun DH; Zhang L; Pan YJ; Dong XW; Li JQ; Xue JY; Zhou YY; Yang HP; Li Y
Platelets; 2016 Jul; 27(5):440-5. PubMed ID: 26830862
[TBL] [Abstract][Full Text] [Related]
15. Administration of Ticagrelor and Double-Dose Clopidogrel Based on Platelet Reactivity Determined by VerifyNow-P2Y12 for Chinese Subjects After Elective PCI.
Wu X; Liu G; Lu J; Zheng XX; Cui JG; Zhao XY; Huang XH
Int Heart J; 2017 Apr; 58(2):167-173. PubMed ID: 28321022
[TBL] [Abstract][Full Text] [Related]
16. Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial.
Kim JS; Han DC; Jeong YH; Park DW; Sohn CB; Hwang KW; Lee SH; Choi JH; Chon MK; Lee SY; Hwang J; Kim IS; Lee SM; Han J; Noh M; Kim CH; Chun KJ; Park YH; Kim JH
Thromb Haemost; 2016 Jan; 115(1):213-21. PubMed ID: 26581884
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation.
Cho JR; Rollini F; Franchi F; DeGroat C; Bhatti M; Dunn EC; Ferrante E; Muniz-Lozano A; Suryadevara S; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2015 Jul; 8(8):1075-1083. PubMed ID: 26117466
[TBL] [Abstract][Full Text] [Related]
18. Comparison of platelet inhibition by prasugrel versus ticagrelor over time in patients with acute myocardial infarction.
Perl L; Zemer-Wassercug N; Rechavia E; Vaduganathan M; Orvin K; Weissler-Snir A; Lerman-Shivek H; Kornowski R; Lev EI
J Thromb Thrombolysis; 2015 Jan; 39(1):1-7. PubMed ID: 25085573
[TBL] [Abstract][Full Text] [Related]
19. Selection of P2Y12 antagonist, treatment initiation, and predictors of high on-treatment platelet reactivity in a "Real World" registry.
Motovska Z; Ondrakova M; Bednar F; Knot J; Ulman J; Maly M
Thromb Res; 2015 Jun; 135(6):1093-9. PubMed ID: 25917561
[TBL] [Abstract][Full Text] [Related]
20. Immature platelet fraction and high-on treatment platelet reactivity with ticagrelor in patients with acute coronary syndromes.
Verdoia M; Sartori C; Pergolini P; Nardin M; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G
J Thromb Thrombolysis; 2016 May; 41(4):663-70. PubMed ID: 26370198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
